Accelerating Biomedical Innovation Act

Hozzl · 2024-02-16T21:08:00Z

Explore the details of Senate Bill 1441 Accelerating Biomedical Innovation Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

2/16/2024, 9:08 PM

Summary of Bill S 1441

Bill 118 s 1441, also known as the Accelerating Biomedical Innovation Act, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to streamline the process of bringing new biomedical innovations to market in order to improve healthcare outcomes for Americans.

One key aspect of the bill is the establishment of a new regulatory pathway for certain medical devices and drugs that have the potential to significantly impact public health. This pathway would allow for expedited review and approval of these products, while still maintaining rigorous safety and efficacy standards.

Additionally, the bill includes provisions aimed at increasing collaboration between government agencies, industry stakeholders, and academic researchers in order to foster innovation and accelerate the development of new medical technologies. This would involve creating new grant programs and incentives to encourage collaboration and investment in biomedical research. Furthermore, the bill seeks to address barriers to innovation by streamlining the regulatory process, reducing administrative burdens, and promoting the use of cutting-edge technologies in the development and evaluation of new medical products. Overall, the Accelerating Biomedical Innovation Act aims to promote innovation in the healthcare industry, improve patient access to new and potentially life-saving treatments, and ultimately enhance the overall quality of healthcare in the United States.

Congressional Summary of S 1441

Accelerating Biomedical Innovation Act

This bill requires the Department of Health and Human Services to establish, through a consortium of institutions of higher education, a center to accelerate the development of advanced medical countermeasures. (These are certain medical products that may be used to diagnose, prevent, or treat conditions associated with chemical, biological, radiological, or nuclear threats or emerging infectious diseases during public health emergencies.)

The center must work on drugs or devices that are selected by the Biomedical Advanced Research and Development Agency (BARDA). A drug or device is eligible for selection if it incorporates a novel technology (or uses an existing technology in a novel way) in a manner that substantially (1) furthers the development of a drug or device of interest, (2) fulfills an unmet need, or (3) develops the manufacturing process for a drug or device.

The bill also requires BARDA to coordinate with international partners to encourage global efforts to advance medical countermeasures.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1441

Bill S 1441 is currently in the status of Bill Introduced since May 4, 2023. Bill S 1441 was introduced during Congress 118 and was introduced to the Senate on May 4, 2023. Bill S 1441's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of May 4, 2023

Bipartisan Support of Bill S 1441

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1441

Primary Policy Focus

Health

Alternate Title(s) of Bill S 1441

Accelerating Biomedical Innovation Act

A bill to establish a Center for Biomedical Innovation and Development in order to accelerate innovation and development of advanced medical countermeasure products.